Long-Term Benefits of Bilateral Salpingo-Oophorectomy Study Reference: Prospective Cohort Study; JAMA Surgery (2026) Many women with a family history of ovarian cancer or a confirmed BRCA1 or BRCA2 pathogenic variant elect to undergo risk-reducing surgery to manage their lifetime cancer risk. Looking at calculated outcomes from a large prospective cohort of 5,713 women, this study measures the protective benefits of bilateral salpingo-oophorectomy (BSO). The findings demonstrate substantial reductions in both ovarian cancer incidence and overall mortality; this evidence provides clear guidance for clinicians and women navigating prophylactic surgical decisions. Key Points Substantial Risk Reduction: Bilateral salpingo-oophorectomy lowers the risk of ovarian, fallopian tube, and primary peritoneal cancers by approximately 80%. Overall Survival Advantage: Prophylactic surgery significantly reduces all-cause mortality among women carrying BRCA pathogenic variants. Critical Importance o...

The Case for Prehabilitation in Advanced Ovarian Cancer Study Reference: Gynecologic Oncology (2026)   Prehabilitation, a targeted program combining optimised nutrition, physical exercise, smoking/alcohol cessation, and mental health support, improves how patients with advanced ovarian cancer handle chemotherapy given before surgery. This matched study of 116 patients showed that those undergoing prehabilitation tolerated higher relative doses of chemotherapy and were significantly more likely to achieve complete surgical removal of all visible tumour tissue. Importantly, these benefits extended to patients aged 70 and older, a group that typically struggles with treatment tolerance. Key Findings Higher Chemo Tolerance: Patients in the prehabilitation group completed their planned chemotherapy cycles with fewer side-effect delays or dose reductions. Better Surgical Outcomes: Building physical reserve before interval surgery led to higher rates of complete cancer removal with no...

Vitamin D in Ovarian Cancer Recurrence. Study Reference: Laboratory / Translational Study   Ovarian cancer often recurs with poor outcomes, making recurrence prevention a major research focus. Emerging evidence shows that platinum chemotherapy can trigger non-stem cancer cells to convert into chemoresistant stem cells,and relapse. Vitamin D limits this conversion. Chemo treatment exacerbates vitamin D deficiency. Since   20% of Australian women are already vitamin D deficient ( a figure rising significantly in winter), routine testing and supplementation offer a safe, accessible strategy to help limit resistance and reduce recurrence risk. Key Points Driver of Relapse: Platinum chemotherapy may change cancer cells into stem-like cells, causing chemoresistance. Targeted Mechanism: Vitamin D  acts as a brake on this process, helping maintain chemotherapy sensitivity. Common Deficiency: About 1 in 5 Australian women are vitamin D deficient, with higher rates during ...

Therapeutic Vaccines for Ovarian Cancer: Is Clinical Reality Close? Study Reference: Systematic Review / Clinical Trial Analysis   The prospect of therapeutic vaccine therapy for ovarian cancer has generated interest for decades; such vaccines function by mobilising a targeted immune response against specific tumour antigens. While platforms using DNA, mRNA, peptides, and dendritic cells have streamlined vaccine manufacturing, clinical progress remains largely exploratory. A comprehensive review of 136 registered trials shows that over 90% remain in early Phase I or II, and no therapeutic vaccine has yet demonstrated clinical efficacy in Phase III trials. Consequently, current clinical development is shifting toward combination strategies (such as targeted antibody-drug conjugates) to overcome immune suppression. Key Points Exploratory Stage: Three  decades of research show that most therapeutic vaccine trials for ovarian cancer remain limited to early safety and immunogenici...